Table 7.

Meta-Analyses of Randomized Trials of Blood Pressure–Lowering Treatment on Prevention of Dementia

AuthorYear of PublicationStudiesSample Size (No. of Events/No. of Patients)Type of EffectP for HeterogeneityMain Results
Birns et al4542006PROGRESS642/18 196Fixed0.180.89 (95% CI 0.75–1.04); P=0.15
SCOPE
SHEP
Syst-Eur
Feigin et al4532005PROGRESS883/23 505Random0.060.80 (95% CI 0.63–1.02); P=0.07
SCOPE
SHEP
Syst-Eur
Peters et al4442008HYVET786/16 595Random0.490·87 (95% CI 0.76–1.00); P=0.045
PROGRESS
SHEP
Syst-Eur
McGuinness et al4562008SCOPE232/15 295Fixed0.160.89 (95% CI 0.69–1.16); P=0.38
SHEP
Syst-Eur
McGuinness et al4552009HYVET495/15 427Fixed0.300.89 (95% CI 0.74–1.07); P=0.21
SCOPE
SHEP
Syst-Eur
  • PROGRESS indicates Perindopril Protection Against Recurrent Stroke Study; SCOPE, Study on Cognition and Prognosis in the Elderly; SHEP, Systolic Hypertension in the Elderly Program; Syst-Eur, Systolic Hypertension in Europe; CI, confidence interval; and HYVET, Hypertension in the Very Elderly Trial.